Antibodies to paliperidone haptens and use thereof

Patent metadata

Field	Value
Publication number	US-10370457-B2
Application number	US-201715410425-A
Country	US
Kind code	B2
Filing date	Jan 19, 2017
Priority date	Aug 21, 2012
Publication date	Aug 6, 2019
Grant date	Aug 6, 2019

Abstract

Disclosed is an antibody which binds to paliperidone, which can be used to detect paliperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of paliperidone, including multiplex detection of aripiprazole, olanzapine, quetiapine, risperidone and paliperidone in a single lateral flow assay device.

First claim

What is claimed is:

1. A method of producing an antibody or a binding fragment thereof which binds to paliperidone, the method comprising:
(i) selecting a host for antibody production; and
(ii) inoculating the host with a conjugate of a compound of Formula I and an immunogenic carrier, wherein the host produces an antibody which binds to paliperidone,

wherein
L 1 is OC(O)(CH 2 ) n , or O(CH 2 ) n ;
wherein n is 2 or 3;
L 2 is NHC(O),

or absent;
L 3 is (CH 2 ) m CO 2 H, or

wherein m is 0, 1, 2, or 3; provided that m may only be 0 if L 2 is absent, and further provided that when L 2 is absent L 3 is

2. A method of producing a hybridoma cell line capable of producing a monoclonal antibody which binds to paliperidone, the method comprising:
(i) selecting a host for antibody production;
(ii) inoculating the host with a conjugate of a compound of Formula I and an immunogenic carrier;
(iii) fusing a cell line from said inoculated host with a continuously dividing cell to create a fused cell capable of producing a monoclonal antibody which binds to paliperidone; and
(iv) cloning the fused cell so as to obtain a hybridoma cell line,

wherein
L 1 is OC(O)(CH 2 ) n , or O(CH 2 ) n ;
wherein n is 2 or 3;
L 2 is NHC(O),

or absent;
L 3 is (CH 2 ) m CO 2 H, or

wherein m is 0, 1, 2, 3; provided that m may only be 0 if L 2 is absent, and further provided that when L 2 is absent L 3 is

3. The method of claim 1 , wherein the immunogenic carrier is a protein.

4. The method of claim 3 , wherein the protein is keyhole limpet hemocyanin, bovine thyroglobulin, or ovalbumin.

5. The method of claim 2 , wherein the immunogenic carrier is a protein.

6. The method of claim 5 , wherein the protein is keyhole limpet hemocyanin, bovine thyroglobulin, or ovalbumin.

7. The method of claim 1 , wherein the antibody binding fragment is selected from the group of fragments consisting of Fv, F(ab′), F(ab′)2, scFv, minibody and diabody fragments.

8. The method of claim 1 , wherein the antibody is a monoclonal antibody.

Assignees

• Janssen Pharmaceutica Nv

Inventors

• Hryhorenko Eric
• Sankaran Banumathi
• Decory Thomas R
• Tubbs Theresa
• Colt Linda
• Vliegen Maarten
• Haspeslagh Pieter Rik

Classifications

• A61P25/24

  Antidepressants · CPC title

• A61P25/18

  Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title

• G01N33/94

  involving narcotics {or drugs or pharmaceuticals, neurotransmitters or associated receptors} · CPC title

• C07K16/44 Primary

  against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids} · CPC title

• C07K2317/14

  Specific host cells or culture conditions, e.g. components, pH or temperature · CPC title